Saracatinib in Treating Patients With Prostate Cancer
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This randomized phase II clinical trial is studying how well saracatinib works in treating
patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.